Hepatic fat fraction: MR imaging for quantitative measurement and display - Early experience

Radiology

Volumn 237, Issue 3, 2005, Pages 1048-1055

  Hussain, Hero K ^a   Chenevert, Thomas L ^a   Londy, Frank J ^a   Gulani, Vikas ^a   Swanson, Scott D ^a   McKenna, Barbara J ^a   Appelman, Henry D ^a   Adusumilli, Saroja ^a   Greenson, Joel K ^a   Conjeevaram, Hari S ^b  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOSE TISSUE; ADULT; ARTICLE; CLINICAL ARTICLE; DIAGNOSTIC ACCURACY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; INFORMED CONSENT; INTERMETHOD COMPARISON; LIVER; LIVER BIOPSY; MALE; MEASUREMENT; NONALCOHOLIC FATTY LIVER; NUCLEAR MAGNETIC RESONANCE IMAGING; PHANTOM; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; VALIDATION PROCESS;

ADULT; ALGORITHMS; FATTY LIVER; FEMALE; HUMANS; LIVER FUNCTION TESTS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PHANTOMS, IMAGING;

EID: 27744582271     PISSN: 00338419     EISSN: None     Source Type: Journal    
DOI: 10.1148/radiol.2373041639     Document Type: Article

References (55)

1. Szumowski J, Simon JH. Fat and water signal separation methods. In: Stark DD, Bradley WG Jr, eds. Magnetic resonance imaging. 3rd ed. St Louis, Mo: Mosby, 1999;159-179.
2. Dooms GC, Hricak H, Margulis AR, de Geer G. MR imaging of fat. Radiology 1986;158(1):51-54.
3. Heiken JP, Lee JK, Dixon WT. Fatty infiltration of the liver: evaluation by proton spectroscopic imaging. Radiology 1985;157(3):707-710.
4. Lee JK, Dixon WT, Ling D, Levitt RG, Murphy WA. Fatty infiltration of the liver: demonstration by proton spectroscopic imaging-preliminary observations. Radiology 1984;153(1):195-201.
5. Rosen BR, Carter EA, Pykett IL, Buchbinder BR, Brady TJ. Proton chemical shift imaging: an evaluation of its clinical potential using an in vivo fatty liver model. Radiology 1985;154:469-472.
6. Marks SJ, Moore NM, Ryley NG, et al. Measurement of liver fat by MRI and its reduction by dexfenfluramine in NIDDM. Int J Obes Relat Metab Disord 1997;21(4):274-279.
7. Korobkin M, Giordano TJ, Brodeur FJ, et al. Adrenal adenomas: relationship between histologic lipid and CT and MR findings. Radiology 1996;200:743-747.
8. Reinig JW, Stutley JE, Leonhardt CM, Spicer KM, Margolis M, Caldwell CB. Differentiation of adrenal masses with MR imaging: comparison of techniques. Radiology 1994;192(1):41-46.
9. Mitchell DG, Corvello M, Matteucci T, Petersen RO, Miettinen MM. Benign adrenocortical masses: diagnosis with chemical shift MR imaging. Radiology 1992;185:345-351.
10. Bilbey JH, McLoughlin RF, Kurkjian PS, et al. MR imaging of adrenal masses: value of chemical-shift imaging for distinguishing adenomas from other tumors. AJR Am J Roentgenol 1995;164:637-642.
11. Leroy-Willig A, Bittoun J, Luton JP. A step forward in the characterization of adrenal cortical lesions [letter]. Radiology 1993;188(3):880-881.
12. Tsushima Y, Ishizaka H, Matsumoto M. Adrenal masses: differentiation with chemical shift, fast low-angle shot MR imaging. Radiology 1993;186(3):705-709.
13. Mayo-Smith WW, Lee MJ, McNicholas MM, Hahn PF, Boland GW, Saini S. Characterization of adrenal masses (<5 cm) by use of chemical shift MR imaging: observer performance versus quantitative measure. AJR Am J Roentgenol 1995;165:91-95.
14. Korobkin M, Lombardi TJ, Aisen AM, et al. Characterization of adrenal masses with chemical shift and gadolinium-enhanced MR imaging. Radiology 1995;197:411-418.
15. Namimoto T, Yamashita Y, Mitsuzaki K, et al. Adrenal masses: quantification of fat content with double-echo chemical shift in-phase and opposed-phase FLASH MR images for differentiation of adrenal adenomas. Radiology 2001;218:642-646.
16. Outwater EK, Siegelman ES, Huang AB, Birnbaum BA. Adrenal masses: correlation between CT attenuation values and chemical shift ratio at MR imaging with in-phase and opposed-phase sequences. Radiology 1996;200:749-752.
17. Slapa RZ, Jakubowski W, Dabrowska E, et al. Magnetic resonance imaging differentiation of adrenal masses at 1.5 T: T2-weighted images, chemical shift imaging, and Gd-DTPA dynamic studies. MAGMA 1996;4:163-179.
18. Outwater EK, Siegelman ES, Radecki PD, Piccoli CW, Mitchell DG. Distinction between benign and malignant adrenal masses: value of T1-weighted chemical-shift MR imaging. AJR Am J Roentgenol 1995;165:579-583.
19. Heinz-Peer G, Honigschnabl S, Schneider B, Niederle B, Kaserer K, Lechner G. Characterization of adrenal masses using MR imaging with histopathologic correlation. AJR Am J Roentgenol 1999;173:15-22.
20. Fujiyoshi F, Nakajo M, Fukukura Y, Tsuchimochi S. Characterization of adrenal tumors by chemical shift fast low-angle shot MR imaging: comparison of four methods of quantitative evaluation. AJR Am J Roentgenol 2003;180:1649-1657.
21. Slapa RZ, Jakubowski W, Januszewicz A, et al. Discriminatory power of MRI for differentiation of adrenal non-adenomas vs adenomas evaluated by means of ROC analysis: can biopsy be obviated? Eur Radiol 2000;10(1):95-104.
22. Outwater EK, Bhatia M, Siegelman ES, Burke MA, Mitchell DG. Lipid in renal clear cell carcinoma: detection on opposed-phase gradient-echo MR images. Radiology 1997;205(1):103-107.
23. Yoshimitsu K, Honda H, Kuroiwa T, et al. MR detection of cytoplasmic fat in clear cell renal cell carcinoma utilizing chemical shift gradient-echo imaging. J Magn Reson Imaging 1999;9:579-585.
24. Yoshimitsu K, Honda H, Kuroiwa T, et al. Fat detection in granular-cell renal cell carcinoma using chemical-shift gradient-echo MR imaging: another renal tumor that contains fat. Abdom Imaging 2000;25:100-102.
25. Martin J, Sentis M, Zidan A, et al. Fatty metamorphosis of hepatocellular carcinoma: detection with chemical shift gradient-echo MR imaging. Radiology 1995;195:125-130.
26. Mulhall BP, Ong JP, Younossi ZM. Non-alcoholic fatty liver disease: an overview. J Gastroenterol Hepatol 2002;17(11):1136-1143.
27. Clark JM, Diehl AM. Nonalcoholic fatty liver disease: an underrecognized cause of cryptogenic cirrhosis. JAMA 2003;289(22):3000-3004.
28. Dixon WT. Simple proton spectroscopic imaging. Radiology 1984;153:189-194.
29. Borrello JA, Chenevert TL, Meyer CR, Aisen AM, Glazer GM. Chemical shift-based true water and fat images: regional phase correction of modified spin-echo MR images. Radiology 1987;164(2):531-537.
30. Glover GH. Multipoint Dixon technique for water and fat proton and susceptibility imaging. J Magn Reson Imaging 1991;1(5):521-530.
31. Glover GH, Schneider E. Three-point Dixon technique for true water/fat decomposition with BO inhomogeneity correction. Magn Reson Med 1991;18(2):371-383.
32. Lodes CC, Felmlee JP, Ehman RL, et al. Proton MR chemical shift imaging using double and triple phase contrast acquisition methods. J Comput Assist Tomogr 1989;13(5):855-861.
33. Szumowski J, Coshow WR, Li F, Quinn SF. Phase unwrapping in the three-point Dixon method for fat suppression MR imaging. Radiology 1994;192:555-561.
34. Szumowski J, Coshow W, Li F, Coombs B, Quinn SF. Double-echo three-point-Dixon method for fat suppression MRI. Magn Reson Med 1995;34:120-124.
35. Yeung HN, Kormos DW. Separation of true fat and water images by correcting magnetic field inhomogeneity in situ. Radiology 1986;159(3):783-786.
36. Coombs BD, Szumowski J, Coshow W. Two-point Dixon technique for water-fat signal decomposition with B0 inhomogeneity correction. Magn Reson Med 1997;38:884-889.
37. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999;94(9):2467-2474.
38. Glazer GM, Woolsey EJ, Borello J, et al. Adrenal tissue characterization using MR imaging. Radiology 1986;158:73-79.
39. Yao L. Routine opposed-phase FLASH MR imaging does not quantify fat content [letter]. Radiology 2001;221:274-275.
40. Day CP. Non-alcoholic steatohepatitis (NASH): where are we now and where are we going? Gut 2002;50(5):585-588.
41. Falck-Ytter Y, Younossi ZM, Marchesini G, McCullough AJ. Clinical features and natural history of nonalcoholic steatosis syndromes. Semin Liver Dis 2001;21(1):17-26.
42. Younossi ZM, Diehl AM, OngJP. Nonalcoholic fatty liver disease: an agenda for clinical research. Hepatology 2002;35(4):746-752.
43. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Non-alcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999;116(6):1413-1419.
44. Nair S, Mason A, Eason J, Loss G, Perrillo RP. Is obesity an independent risk factor for hepatocellular carcinoma in cirrhosis? Hepatology 2002;36(1):150-155.
45. Marrero JA, Fontana RJ, Su GL, Conjeevaram HS, Emick DM, Lok AS. NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. Hepatology 2002;36(6):1349-1354.
46. Caldwell SH, Oelsner DH, Iezzoni JC, Hespenheide EE, Battle EH, Driscoll CJ. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology 1999;29(3):664-669.
47. Poonawala A, Nair SP, Thuluvath PJ. Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: a case-control study. Hepatology 2000;32(4 pt 1):689-692.
48. Ong J, Younossi ZM, Reddy V, et al. Cryptogenic cirrhosis and posttransplantation nonalcoholic fatty liver disease. Liver Transpl 2001;7(9):797-801.
49. Bugianesi E, Leone N, Vanni E, et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002;123(1):134-140.
50. Bravo AA, Sheth SG, Chopra S. Liver biopsy. N Engl J Med 2001;344(7):495-500.
51. McGill DB, Rakela J, Zinsmeister AR, Ott BJ. A 21-year experience with major hemorrhage after percutaneous liver biopsy. Gastroenterology 1990;99(5):1396-1400.
52. Saadeh S, Younossi ZM, Remer EM, et al. The utility of radiological imaging in non-alcoholic fatty liver disease. Gastroenterology 2002;123(3):745-750.
53. Marsman H, Matsushita T, Dierkhising R, et al. Assessment of donor liver steatosis: pathologist or automated software? Hum Pathol 2004;35(4):430-435.
54. Leroy-Willig A, Bittoun J, Luton JP, et al. In vivo MR spectroscopic imaging of the adrenal glands: distinction between adenomas and carcinomas larger than 15 mm based on lipid content. AJR Am J Roentgenol 1989;153(4):771-773.
55. Leroy-Willig A, Roucayrol JC, Luton JP, Courtieu J, Niesenbaum N, Louvel A. In vitro adrenal cortex lesions characterization by NMR spectroscopy. Magn Reson Imaging 1987;5(5):339-344.